- Home
- KOD vs YMAB Comparison
KOD vs YMAB Comparison
Compare KOD & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- YMAB
- Stock Information
- Founded
- KOD 2009
- YMAB 2015
- Country
- KOD United States
- YMAB United States
- Employees
- KOD N/A
- YMAB N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- YMAB Health Care
- Exchange
- KOD Nasdaq
- YMAB Nasdaq
- Market Cap
- KOD 454.7M
- YMAB 482.4M
- IPO Year
- KOD 2018
- YMAB 2018
- Fundamental
- Price
- KOD $7.50
- YMAB $6.19
- Analyst Decision
- KOD Hold
- YMAB Strong Buy
- Analyst Count
- KOD 4
- YMAB 10
- Target Price
- KOD $8.00
- YMAB $21.10
- AVG Volume (30 Days)
- KOD 448.1K
- YMAB 417.3K
- Earning Date
- KOD 11-14-2024
- YMAB 02-27-2025
- Dividend Yield
- KOD N/A
- YMAB N/A
- EPS Growth
- KOD N/A
- YMAB N/A
- EPS
- KOD N/A
- YMAB N/A
- Revenue
- KOD N/A
- YMAB $84,553,000.00
- Revenue This Year
- KOD N/A
- YMAB $6.09
- Revenue Next Year
- KOD N/A
- YMAB $19.62
- P/E Ratio
- KOD N/A
- YMAB N/A
- Revenue Growth
- KOD N/A
- YMAB N/A
- 52 Week Low
- KOD $2.19
- YMAB $6.01
- 52 Week High
- KOD $11.60
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- KOD 44.49
- YMAB 19.68
- Support Level
- KOD $7.21
- YMAB $6.05
- Resistance Level
- KOD $9.14
- YMAB $6.81
- Average True Range (ATR)
- KOD 0.86
- YMAB 0.49
- MACD
- KOD -0.33
- YMAB -0.02
- Stochastic Oscillator
- KOD 15.73
- YMAB 6.90
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.